Pfizer Corporation

Ge Healthcare Limited

Pfizer Products Inc.

Christopher John Helal

David Andrew Griffith

Patrick Robert Verhoest

Thomas Allen Chappie

Michael Aaron Brodney

Christopher Ryan Butler

Erik Alphie LaChapelle

Nandini Chaturbhai Patel

Laura Ann McAllister

Simone Sciabola

Travis T Wager

Matthew Merrill Hayward

Steven Victor O'Neil

Bethany Lyn Kormos

John Michael Humphrey

Joseph Michael Young

Bruce Nelsen Rogers

Adam Matthew Gilbert

Elizabeth Mary Beck

Justin Ian Montgomery

Jamison Bryce Tuttle

Douglas Scott Johnson

Brian Thomas O'Neill

Lei Zhang

Dennis J Hoover

Jaclyn Louise Henderson

Martin Youngjin Pettersson

Antonia Friederike Stepan

Paul Galatsis

Qingyi Yang

Bengt Langstrom

Chakrapani Subramanyam

Jotham Wadsworth Coe

Scot Richard Mente

Jennifer Elizabeth Davoren

Ivan Viktorovich Efremov

Amy Beth Dounay

David Lawrence Firman Gray

Jeffrey W Raggon

Joseph Scott Warmus

Yuan Zhang

Brian Kenneth Raymer

Daniel Wei-Shung Kung

Matthew Forrest Sammons

Jana Polivkova

Damien Webb

Michelle Renee Garnsey

Ramalakshmi Yegna Chandrasekaran

Ravi G Kurumbail

Stephane Caron

Karen Jean Coffman

Matthew Richard Reese

Jinshan Michael Chen

Yajing Lian

Luis Angel Martinez-Alsina

Michelle Marie Claffey

Natasha Mariam Kablaoui

Eddie Yang

Yong Tao

Gunnar Antoni

Kevin Alexander Ogilvie

Erik Alphie Lachapelle

Steven Victor O'neil

Jamison Byrce Tuttle

John Arthur Allen

Edward Raymond Guilmette

Anthony Richard Harris

Deane Milford Nason

Wenjian Xu

Colin Richard Rose

Jia Zhi Sheng

Susan Beth Sobolov-Jaynes

Timothy James McCarthy

Nga M Do

Laura Ann Mcallister

David Lawrence Gray

Dennis Jay Hoover

Aaron Christopher Smith

Travis T Wagner

Deane Milford Ii Nason

Timothy John Mccarthy

Susan Beth Jaynes-Sobolove

The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X, X, R, R, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

Piperazine azaspiro derivatives

The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R, R, R, R, R, Rand n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.

Tricyclic compounds and their use as phosphodiesterase inhibitors

The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X, X, R, R, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder. 

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R, Rand Rare as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy. 

Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors

The present invention provides novel cyclic substituted imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof; wherein R, R, R, R, R, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy. 

Cyclic substituted imidazo[4,5-c]quinoline derivatives

The present invention provides, in part, heterocyclic spiro compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Heterocyclic spiro compounds as MAGL inhibitors

The present invention is directed to PDE4B inhibitors of Formula I: (I) or a pharmaceutically acceptable salt thereof, wherein the substituents R, R, R, and Rare as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds. 

6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors

The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R, R, R, R, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.

Imidazopyridazine compounds

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors

The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R, R, R, and Rare as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.

The present invention is directed to pyrazolopyrimine compounds or pharmaceutically acceptable salts which are inhibitors of PDE4 isozymes, especially with a binding affinity for PDE4B isoform, and compositions thereof.

Pyrazolopyrimidine compounds

Growing community of inventors

Mystic, CT, United States of America

Christopher John Helal